Pyrrolidine dithiocarbamate sensitizes U251 brain glioma cells to temozolomide via downregulation of MGMT and BCL-XL

JUN-HAI TANG¹, GUO-HAO HUANG¹, KE-JIE MOU¹, ERIC ERQUAN ZHANG², NINGNING LI³, LEI DU¹, XIAO-PENG ZHU¹, LING CHEN⁴, HUI YANG¹, KE-BIN ZHANG⁵ and SHENG-QING LV¹

¹Department of Neurosurgery, Xinqiao Hospital, Third Military Medical University, Chongqing 400037; ²National Institute of Biological Sciences, Beijing 102206, P.R. China; ³Division of Neuropathology and Department of Neurodegenerative Disease, Institute of Neurology, University College London, London WC1N 3BG, UK; ⁴Department of Neurosurgery, Chinese PLA General Hospital, Beijing 100853; ⁵Central Laboratory, Xinqiao Hospital, Third Military Medical University, Chongqing 400037, P.R. China

Received November 21, 2015; Accepted December 16, 2016

DOI: 10.3892/ol.2017.6849

Abstract. The current study investigated the effect of pyrrolidine dithiocarbamate (PDTC) on the proliferation, apoptosis, cell cycle and sensitivity to temozolomide (TMZ) of the U251 glioma cell line. Proliferation, apoptosis and cell cycle analysis of U251 cells following treatment with PDTC and TMZ was determined by an MTT assay and flow cytometry, respectively. The mRNA and protein expression levels of O-6-methylguanine-DNA methyltransferase (MGMT), B-cell lymphoma extra-large (BCL-XL) and survivin were further determined by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and western blotting analysis. The results revealed that treatment with TMZ, PDTC and TMZ + PDTC significantly inhibited cell proliferation, induced apoptosis and contributed to cell cycle arrest in U251 cells. A combination of PDTC and TMZ induced the highest rates of proliferation inhibition and apoptosis. PDTC treatment markedly reduced the expression levels of MGMT, BCL-XL and survivin. The expression levels of MGMT and BCL-XL were significantly upregulated by TMZ, but not by combination treatment of TMZ and PDTC. The results of the present study suggest that treatment with PDTC inhibits cell proliferation, induces apoptosis and cell cycle arrest, and enhances sensitivity to TMZ in U251 cells, which is partly induced by downregulation of MGMT and BCL-XL.

Introduction

Brain glioma is the most common type of primary tumor in the central nervous system and is one of the leading causes of mortality in patients with cancer (1,2). Currently an integrated therapeutic method of surgery, radiotherapy and chemotherapy has been adopted in clinical high-grade glioma treatment (3). Patients receiving radiotherapy with concomitant and adjuvant temozolomide (TMZ), demonstrated certain advances in progression-free survival (PFS) and 5-year survival; however, the rate of total survival has not improved (4). TMZ is an oral administered alkylating chemotherapeutic drug, capable of crossing the blood-brain barrier and has been widely used to treat refractory anaplastic astrocytoma and newly diagnosed glioblastoma multiforme (5,6). The therapeutic benefits of TMZ treatment primarily depend on its ability to methylate the O-6 positions of guanine residues (7). This methylation induces irreversible damage to the DNA and triggers abnormal activation of the repair system, leading to cycle arrest and cell death (7). However, certain tumor cells are able to repair this type of DNA damage by expression of the protein, O6-alkylguanine DNA alkyltransferase (AGT), encoded in humans by the O-6-methylguanine-DNA methyltransferase (MGMT) gene (8). A previous study revealed that the presence of MGMT protein diminishes the therapeutic efficacy of TMZ in brain tumors; the study also indicated that high MGMT expression predicts poor response to TMZ and little benefit from chemotherapy with TMZ (9). Conversely, in specific cases, suppressed synthesis of MGMT due to methylation of the MGMT gene promoter is considered a good prognostic factor in TMZ treated patients with glioma (10). At the molecular level, several mechanisms, including nuclear factor-κB (NF-κB) (11), tumor protein 53 (12), specificity protein 1 (12), clone of myelocytomatosis viral oncogene in cancer (Myc) (13) and c-Jun N-terminal kinase (JNK) (14) mediated signaling pathways, have been suggested to be involved in the transcription regulation of MGMT. As a consequence, modifying
MGMT expression via its transcription factors has been proposed as a means to sensitize tumor cells to TMZ (15).

NF-κB represents a family of ubiquitous transcription factors that modulate the expression levels of genes by binding to specific κB sites (16). The activity of NF-κB is regulated by the NF-κB inhibitory protein (IkB) (17). In the inactive state, IkB binds to and sequesters NF-κB family members in the cytoplasm (17). Following NF-κB signaling pathway activation by various stimuli, including hypoxia, cytokines and chemotherapeutic drugs, IkB is phosphorylated by IkB kinase (IKK) (17); phosphorylated IkB is subjected to ubiquitination and kinase proteasome-mediated degradation, which results in the activation and translocation of NF-κB to the nucleus (17).

Excluding its roles in innate immunity and inflammation, the NF-κB signaling pathway was revealed to regulate a number of cellular processes, including cell proliferation, differentiation and apoptosis (16-18). Furthermore, it has been reported that activation of the NF-κB signaling pathway may also contribute to tumor initiation, progression and resistance to radiotherapy or chemotherapy (19,20). High constitutive NF-κB activity has been observed in numerous lymphoid and myeloid tumors (21), in addition to various solid tumors, including pancreatic cancer (22), glioblastoma (23) and breast cancer (24). Certain recent studies demonstrated that hypoxia may activate the NF-κB signaling pathway, induce the epithelial-mesenchymal transition of breast cancer cells (24), cause invasion of prostatic cancer cells and contribute to gemcitabine mediated resistance (25).

The present study focused on the association between NF-κB activity and glioma cell progression and chemotherapy. The critical roles which NF-κB serves in the progression and chemoresistance of gliomas have been demonstrated by accumulating experimental evidence (26). Similar to MGMT, NF-κB also contributes to the development of glioma resistance to alkylating agents (27). Furthermore, certain studies indicated that NF-κB associated chemoresistance was partially mediated by the NF-κB/MGMT signaling pathway, which may be activated by alkylating drugs (28,29). In order to determine the effect of inhibiting NF-κB activity on glioma cell viability and sensitivity to alkylating drugs, in addition to clarifying the underlying molecular mechanisms, the present study compared the proliferation inhibiting, cell apoptosis inducing and cell cycle arresting effects of TMZ, pyrrolidine dithiocarbamate (PDTC) and TMZ + PDTC combined. This was followed by determining the expression level alterations of MGMT and other associated genes, including B-cell lymphoma extra large (BCL-XL) and survivin. The present study aimed to further current understanding of the effects and the underlying molecular mechanisms of inhibiting NF-κB activity in glioma therapy, and aid the development of a clinical strategy with combined TMZ and NF-κB inhibitors.

Materials and methods

Chemicals and reagents. Dulbecco’s modified Eagle’s medium (DMEM), fetal bovine serum (FBS) and TRIzol® were obtained from Invitrogen (Thermo Fisher Scientific, Inc., Waltham, MA, USA); temozolomide and dimethyl sulfide (DMSO) were purchased from Sigma Aldrich (Merck Millipore, Darmstadt, Germany); the MTT, cell cycle and apoptosis analysis kit, Annexin V-fluorescein isothiocyanate (FITC) kit, Bradford protein assay kit, radioimmunoprecipitation assay, lysis buffer, phenyl methanesulfonyl fluoride and BeyoECL Plus were all purchased from Beyotime Institute of Biotechnology (Haimen, China). A Prime Script™ RT Master Mix was obtained from Takara Bio, Inc. (Otsu, Japan); a KAPA SYBR Fast qPCR kit was purchased from Kapa Biosystems, Inc. (Wilmington, MA, USA). The primary antibodies used for western blot analysis were mouse anti MGMT, BCL-XL, survivin and β-actin, and the secondary antibodies used were horseradish peroxidase-conjugated goat anti-mouse IgG (H + L), all supplied by Abcam (Cambridge, UK).

Cell lines and cell culture. The U251 human glioblastoma cell line was purchased from the National Institute of Biological Sciences (Beijing, China) and cultured in DMEM (DMEM basic 1X 1199500) supplemented with 10% FBS (10099141) (both from Gibco; Thermo Fisher Scientific, Inc.). Cells were incubated for about 6 months at 37°C in a humidified chamber with 5% CO₂.

MTT assays for cell proliferation. Exponentially growing U251 cells were digested and re-plated into 96-well plates (4x10³ cells; 100 µl/well; six repeat wells in each column). These plates were randomly divided into four groups: TMZ group, PDTC group, TMZ + PDTC group and control group. Following an incubation of 24 h, the groups were cultured as follows: Medium of the TMZ group was replaced with fresh medium (DMEM basic 1X with 10% FBS) containing 200 µmol/l TMZ, PDTC group was divided into three subgroups and medium of the three subgroups were replaced with fresh medium (DMEM basic 1X with 10% FBS) containing 20, 50 and 80 µmol/l PDTC; TMZ + PDTC group was divided into three groups and medium of the three subgroups were replaced with fresh medium (DMEM basic 1X with 10% FBS) containing 200 µmol/l TMZ and 20 µmol/l PDTC, 200 µmol/l TMZ and 50 µmol/l PDTC or 200 µmol/l TMZ and 80 µmol/l PDTC. DMSO was added into the control group. A column from each group was evaluated every 24 h and 10 µl/well MTT (5 mg/ml) was added to six wells in one column. Following incubation for 4 h, 100 µl/well formazan solution was added and incubated for an additional 4 h. Absorbance was determined at 570 nm, using an Ultra multi-functional microplate reader (Tecan Group, Ltd., Durham, NC, USA). The evaluation was performed for five consecutive days and the cell inhibition rates were calculated as follows: Rate of proliferation inhibition = [mean optical density (OD) value of control cells - mean OD value of treated cells]/mean OD value of control cells. The results were confirmed by ≥3 repetitions.

Flow cytometry detecting cell apoptosis and cell cycle distribution. U251 cells (8x10⁵) were re-plated in 6-well plates (9.6 cm²). Fresh medium (DMEM basic 1X with 10% FBS) was added with the following supplements: 200 µmol/l TMZ into the TMZ group; 20 µmol/l PDTC, 50 µmol/l PDTC and 80 µmol/l PDTC into the three subgroups of the PDTC group, respectively; 200 µmol/l TMZ and 20 µmol/l PDTC, 200 µmol/l TMZ and 50 µmol/l PDTC or 200 µmol/l TMZ and 80 µmol/l PDTC into the three subgroups of the TMZ + PDTC group, respectively; 200 µmol/l TMZ and 100 µmol/l PDTC.
Table I. Reaction system and conditions for RT-qPCR analysis.

| Reagents                  | Amount added, µl | Step | Action               |
|---------------------------|------------------|------|----------------------|
| 2X KAPA SYBR Fast qPCR    |                  | 1.   | 95°C for 2 min       |
| Master Mix Universal      | 7.50             | 2.   | 95°C for 5 sec       |
| 10 µM forward primer      | 0.15             | 3.   | 60°C for 20 sec, value read |
| 10 µM reverse primer      | 0.15             | 4.   | Repeat 2 and 3 for 39 repetitions |
| cDNA template             | 1.00 (50.00 ng)  | 5.   | Melt curve 65°C to 95°C in increments of 0.5°C, for 5 sec each, value read, end. |
| PCR-grade water           | 6.20             |      |                      |

RT-qPCR, reverse transcription-quantitative polymerase chain reaction.

into the fourth subgroup of the TMZ + PDTC group (only added in this part of the experiment); and the solvent DMSO was added into control group. Following incubation for 24 h, cells were digested by trypsinization and detached cells in the medium were collected. Cells were harvested and washed with cold PBS, 5x10^6 cells were collected in 1.5 ml microtubes (MCT-150; Axygen, Union City, CA, USA). Subsequently, cells were gently resuspended in 100 µl 1X binding buffer with 5 µl Annexin V-FITC and 5 µl propidium iodide (PI) staining solution. Following incubation for 15 min in the dark at 25°C, cells were mixed gently with 40 µl 1X binding buffer and filtered with a 0.45 µm filter unit Millex-HV (Merck Millipore), prior to flow cytometry analysis (FACSCalibur™; BD Biosciences, San Jose, CA, USA). Subsequent analyses of flow cytometry data were performed using CellQuest Pro software (version 5.1; BD Biosciences). For cell cycle distribution evaluation, cells (groups with 100 µmol/l PDTC were removed) were collected and resuspended with cold ethanol (70%) and fixed in ethanol for 12 h at 4°C, prior to being harvested. Following washing with cold PBS twice, cells were mixed gently with 500 µl PI and incubated for 30 min in the dark at 35°C. Cell cycle distribution was determined using flow cytometry.

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis. Cells (5x10^6 cells initially seeded) were cultured in 6-well plates and the following treatment was administered for 48 h at 37°C in a humidified chamber containing 5% CO₂; 80 µmol/l PDTC to the PDTC group, 200 µmol/l TMZ to the TMZ group, 200 µmol/l TMZ and 50 µmol/l PDTC to the TMZ + PDTC group, and DMSO to the control groups. Total RNA was extracted using TRIzol® reagent, according to the manufacturer's instructions. First-strand cDNA was reverse transcribed from 1 µg total RNA using the Prime Script™ RT Master Mix, and target gene mRNA was amplified by the KAPA SYBR Fast qPCR kit, using a Bio-Rad CFX96™ real-time system (Bio-Rad Laboratories, Inc., Hercules, CA, USA). The reaction system (15 µl), PCR conditions and gene specific primers are presented in Tables I and II.

Western blot analysis. Cells were cultured in 6-cm dishes, following grouping and treatment as in RT-qPCR analysis; the cell lysates were harvested and protein level was evaluated using Bradford Protein Assay kit (P0006C; Beyotime Institute of Biotechnology). Equal amounts of total protein (80-200 µg) were separated using 10% SDS-PAGE and transferred to polyvinylidene difluoride membranes. Subsequent to blocking with 5% fat-free milk and 0.1% Tween-20 in PBS-T for 1 h at room temperature, the membranes were incubated with a dilution of anti-MGMT (mouse monoclonal MT3.1 to MGMT; ab39253; 1:500), anti-BCL-XL (mouse monoclonal MT3.1 to MGMT; ab39253; 1:500), anti-survivin (mouse monoclonal 60.11 to survivin; ab93274; 1:800) and anti-β-actin antibodies. Horseradish peroxidase-conjugated anti-mouse secondary antibodies (goat anti-mouse IgG H&L horseradish peroxidase pre-adsorbed; ab97040; 1:1200; Abcam) were used, and bound antibodies were detected using the BeyoECL system (P0018; Beyotime Institute of Biotechnology).

Statistical analysis. Data are presented as the mean ± standard deviation. All statistical analyses were performed using SPSS 13.0 software (SPSS, Inc., Chicago, IL, USA). The Student's t-test (one sample or independent-samples t-test) was used to analyze the difference between the means of the treatment group and the control group. One-way analysis of
variance (ANOVA) was used to analyze the significance among ≥3 groups and Fisher's least significant difference method for multiple comparisons was used when the probability for ANOVA was statistically significant. Methods of nonparametric statistical analysis including the Mann-Whitney U Test and Kruskal-Wallis ANOVA, were used when the variances did not pass the Levene test for normality or homogeneity. P<0.05 was considered to indicate a statistically significant difference.

Results

Combining TMZ and PDTC induces the highest proliferation inhibition rate. TMZ, PDTC and TMZ + PDTC treatments all significantly suppressed the proliferation of U251 cells (P<0.05). Cell OD values decreased with increasing PDTC concentrations (a: P<0.05, compared with the control group; b: P<0.05, compared with the control group and 20 µmol/l PDTC group; c: P<0.05, compared with the control group and 50 µmol/l PDTC group; independent-samples t test and one-way ANOVA followed by LSD analysis or Kruskal-Wallis test). Cell OD values of TMZ + PDTC groups were significantly lower than those of the TMZ group and the corresponding PDTC groups (d: P<0.05, compared with the TMZ group and 20 µmol/l PDTC group; e: P<0.05, compared with the TMZ group, 50 µmol/l PDTC group and TMZ + 20 µmol/l PDTC group; f: P<0.05, compared with TMZ group and 80 µmol/l PDTC group; one-way ANOVA followed by LSD analysis or the Kruskal-Wallis test). (B) Cell proliferation inhibition rates in three representative groups. The inhibition rates of the TMZ + 50 µmol/l PDTC treatment group were significantly higher, compared with 200 µmol/l TMZ or 80 µmol/l PDTC treatments at 24-120 h (a: P<0.05, compared with the TMZ group and PDTC group; b: P<0.05, compared with the TMZ group, 50 µmol/l PDTC group and TMZ + 20 µmol/l PDTC group; c: P<0.05, compared with TMZ group and 80 µmol/l PDTC group; one-way ANOVA followed by LSD analysis). OD, optical density; TMZ, temozolomide; PDTC, pyrrolidine dithiocarbamate; ANOVA, analysis of variance; LSD, least significant difference.

Combination of TMZ and PDTC induces the most significant cell apoptosis. Following an incubation of 24 h, TMZ, PDTC and TMZ + PDTC markedly induced cell apoptosis compared with the control (Fig. 2). TMZ + PDTC induced higher apoptosis rates as compared with TMZ and the corresponding concentrations of PDTC (Table III). The rate of cell apoptosis increased with increasing PDTC concentrations (P<0.05; Table III). However, when treated with 100 µmol/l PDTC or TMZ + ≥50 µmol/l PDTC, cell apoptosis rates reached >93%, and no significant difference had been identified among these groups (P>0.05; Table III).
Table III. Apoptosis rates of U251 cells in distinct groups.

| Group                | Concentration, μmol/l | Early stage, % | Late stage, % | Total apoptosis, % |
|----------------------|-----------------------|----------------|---------------|-------------------|
| Control              |                       | (1.6±0.54)     | (0.8±0.03)    | (2.4±1.03)        |
| TMZ                  | 200                   | (22.8±2.24)    | (3.1±0.75)    | (25.9±3.15)       |
| PDTC                 | 20                    | (2.0±1.41)     | (2.7±0.43)    | (17.9±1.26)       |
|                      | 50                    | (25.8±0.85)    | (5.8±0.91)    | (31.6±1.75)       |
|                      | 80                    | (59.8±2.09)    | (4.1±1.46)    | (63.9±4.24)       |
|                      | 100                   | (71.7±2.76)    | (22.5±2.07)   | (93.2±4.73)       |
| TMZ + PDTC           | 20                    | (26.6±2.27)    | (6.7±0.85)    | (33.3±2.44)       |
|                      | 50                    | (70.2±5.12)    | (21.5±2.57)   | (91.7±5.22)       |
|                      | 80                    | (64.1±3.04)    | (33.2±2.06)   | (97.3±4.46)       |
|                      | 100                   | (57.7±3.55)    | (39.2±2.89)   | (96.9±5.10)       |

Data were presented as the mean ± standard deviation. *P<0.05, vs. control group; †P<0.05, vs. control group and 20 μmol/l PDTC group; ‡P<0.05, vs. control group and 50 μmol/l PDTC group; §P<0.05, vs. control group and 80 μmol/l PDTC group; ¶P<0.05, vs. TMZ group and 20 μmol/l PDTC; ††P<0.05, vs. TMZ group, 50 μmol/l PDTC group and TMZ + 20 μmol/l PDTC group; ‡‡P<0.05, vs. TMZ group, 80 μmol/l PDTC group and TMZ + 50 μmol/l PDTC group; §§P<0.05, vs. TMZ group, 100 μmol/l PDTC group and TMZ + 80 μmol/l PDTC group. All comparisons were carried out using one‑way analysis of variance followed by least significant difference analysis or by the Kruskal‑Wallis test. TMZ, temozolomide; PDTC, pyrrolidine dithiocarbamate.

**PDTC enhances the cell cycle arresting effect of TMZ treatment.** The combination of TMZ and PDTC led to a significant G_0/G_1 cell cycle arresting effect in U251 cells (Fig. 3). The percentage of cells in the G_0/G_1 stage in TMZ + PDTC groups was markedly higher than in the TMZ group (42.4±1.39%) and the corresponding PDTC groups (P<0.05), whereas the percentage of cells in the G_2 stage in TMZ + PDTC groups were markedly lower compared with that in the TMZ group (25.1±1.14%) and the corresponding PDTC groups (P<0.05; Table IV). A higher concentration of PDTC induced a higher proportion of cells in the G_0/G_1 stage; however, TMZ + 80 μmol/l PDTC induced no more significant G_0/G_1 arrest than TMZ + 50 μmol/l PDTC (P<0.05; Table IV).

**PDTC suppresses the expression of MGMT, BCL-XL and survivin.** Following incubation with PDTC for 48 h, the mRNA levels of MGMT, BCL-XL and survivin were significantly reduced (P<0.05; Fig. 4A-C). The protein levels of MGMT, BCL-XL and survivin were also reduced following PDTC treatment (Fig. 4D).

**PDTC counteracts MGMT and BCL-XL upregulation induced by TMZ.** MGMT, BCL-XL and survivin expression levels increased significantly, subsequent to TMZ treatment for 24 h (P<0.05; Fig. 5). However, this upregulation was abrogated by simultaneous treatment with PDTC. MGMT and BCL-XL expression levels in the PDTC + TMZ group were markedly lower compared with that in the TMZ group, whereas survivin expression was not altered significantly (P<0.05; Fig. 5).

**Discussion**

NF-κB serves a number of critical roles in the development, invasion, recurrence and chemoresistance of malignant brain glioma (30). Abnormal constitutive activation of the NF-κB signaling pathway may be identified in a large number of clinical glioma specimens (31). Wang et al (32) revealed that >90% of the 259 human diffuse gliomas included in the study exhibited high activation of NF-κB, and the extent of activation represented by the protein expression level of the p65 subunit was positively associated with glioma grade and malignancy. Highly activated NF-κB may lead to increased expression levels of matrix metalloproteinases (MMPs) (33) and vascular endothelial growth factor (VEGF), which facilitates microvascular invasion and distal metastases of glioblastoma stem cells (GSCs) (34). In conjunction with the high level of constitutive activity, it has previously been demonstrated that numerous alkylating agents may activate NF-κB in glioma cells (35). Contributing to the anti-apoptotic effect of the NF-κB signaling pathway and blocking constitutive or stimulated NF-κB activation may be a potential approach to suppressing glioma cell viability and enhance the efficacy of alkylating drugs (36).

Furthermore, the inhibition of NF-κB by genetic or chemical inhibitors induces apoptosis of various glioma cells and restores the apoptotic response following treatment with ionizing radiation or chemotherapeutic agents, thus reversing NF-κB linked radioresistance or chemoresistance in a number of models (37). For example, when NF-κB function was profoundly suppressed in U87 and U251 glioma cells via the overexpression of non-degradable IκB, chemical agents including carmustine (BCNU), carboplatin, SN38 glucuronide and tumor necrosis factor-α, induced significant proliferation inhibition and apoptosis in these refractory cell lines (29). SN50, a specific NF-κB inhibitor, may induce differentiation and reduce malignant characters (including neuro-sphere formation, motility, invasion and tumor initiation in vivo) of GSCs. The GSCs sensitivity to TMZ and radiotherapy was markedly enhanced by a low dose of SN50 (38). In the present study, another specific NF-κB inhibitor, PDTC, was used: PDTC is membrane permeable and an antioxidant (39). PDTC may reduce the phosphorylation and degradation of IκB and...
subsequently block NF-κB activation and nuclear translocation (40). In conjunction with previous studies (28,41,42), the results of the MTT assay and flow cytometry conducted in the present study demonstrated that a low concentration of PDTC may markedly inhibit proliferation and induce apoptosis in U251 cells. Furthermore, the combined treatment of TMZ and PDTC led to a significant increase in proliferation-inhibition rate, apoptosis rate and a more significant cell cycle arrest, as compared with TMZ or PDTC treatment alone (Figs. 1-3). These results indicated a synergistic effect between TMZ and NF-κB inhibitors; a comprehensive understanding of the molecular mechanisms underlying this synergistic action may facilitate the exploration of more efficacious NF-κB inhibitors and alkylating agents.

As previously described, MGMT is a key factor of chemoresistance in gliomas (10) and inhibiting the NF-κB signaling pathway may markedly enhance TMZ chemotherapeutic efficacy in U251 cells (37). The results of current study suggest that NF-κB inhibitors mediate their killing effects by inhibiting a potential NF-κB/MGMT signaling pathway. In order to further support this suggestion, evidence is required which indicates that an NF-κB/MGMT signaling pathway exists in glioma cells and that NF-κB inhibitors, including PDTC, significantly reduce MGMT expression in glioma cell lines following treatment with alkylating agents. A number of studies have previously demonstrated the existence of an NF-κB/MGMT signaling pathway in glioma cells (15,43,44). Two putative NF-κB binding sites within the MGMT promoter region have been discovered by Lavon et al (28), demonstrated

Figure 3. Flow cytometry analysis of U251 cells in G0/G1, S and G2 phases following treatment with PDTC in various concentrations. (A) Control, (B) 200 µmol/l TMZ, (C) 20 µmol/l PDTC, (D) TMZ + 20 µmol/l PDTC, (E) 50 µmol/l PDTC, (F) TMZ + 50 µmol/l PDTC, (G) 80 µmol/l PDTC, (H) TMZ + 80 µmol/l PDTC. (P1) G0/G1 phase, (P2) S phase, (P3) G2 phase. PDTC, pyrrolidine dithiocarbamate; TMZ, temozolomide.
a specific and direct interaction of NF-κB at each of these sites. They further revealed that forced expression of the NF-κB subunit p65 in HEK293 cells and glioma cells induced an increase in MGMT expression levels, whereas the addition of the NF-κB inhibitor IκB completely abrogated this induction (28). MGMT expression was revealed to be attenuated by fluoxetine via disrupting the NF-κB signaling pathway and consequently sensitized 98 G, SF767 and U251 glioma cells to TMZ treatment (44). Similarly, the present study identified markedly lower MGMT expression levels in PDTC -treated U251 cells (Fig. 4). As aforementioned, alkylating agents may activate the NF-κB signaling pathway, and NF-κB serves an important role in MGMT regulation. Also, it has previously been revealed that alkylating drugs stimulate MGMT expression in glioma cells (45). Therefore, an NF-κB/MGMT signaling pathway may be activated by alkylating drugs, in addition to stimulating MGMT expression. Other anti-apoptotic mechanisms may also serve major roles in NF-κB-mediated chemoresistance to alkylating agents (31). In order to confirm these suggestions, the present study treated U251 cells with 100 µmol/l TMZ. As a notable result, significant increases in MGMT expression levels and in two additional NF-κB downstream genes, BCL‑XL and survivin, were demonstrated.

Additional evidence derives from a previous study by Lavon et al (28), which revealed that the suppression of MGMT activity with O6-benzylguanine eradicates the chemoresistance acquired by glioma cell lines, with ectopic p65 or high constitutive NF-κB activity. Despite the understanding that high MGMT expression in resistant glioma cells is stimulated by constitutive or drug-activated high NF-κB activity (29,32), evidence from previous studies supports the present study’s hypothesis of the existence and the contribution of an NF-κB/MGMT signaling pathway towards chemoresistance (28,43,44). However, the questions remain about whether this signaling pathway may be exploited to combat fatal gliomas, and if the efficacy of combined TMZ and PDTC treatment is a result of the downregulation of MGMT. In order to investigate these considerations, the present study compared the expression levels of MGMT in cells treated with TMZ + PDTC and in cells treated with TMZ alone, it was revealed that the expression level of MGMT was significantly reduced by the addition of PDTC (Fig. 5). These results are supported by a number of similar previous studies (28,44). For

Table IV. Cell cycle distribution of U251 cells in distinct groups.

| Group       | Concentration, µmol/l | G0/G1, %   | S, %       | G2, %      |
|-------------|-----------------------|------------|------------|------------|
| Control     | (26.0±1.42)           | (10.4±1.36)| (34.2±1.85)|            |
| TMZ         | 200                   | (42.4±1.39) | (9.8±1.71) | (25.1±1.14) |
| PDTC        | 20                    | (38.3±2.52) | (9.5±1.83) | (21.5±0.94) |
|             | 50                    | (47.7±3.32) | (7.9±1.53) | (21.6±3.04) |
|             | 80                    | (50.8±4.05) | (6.8±1.32) | (21.3±2.16) |
| TMZ + PDTC  | 20                    | (49.1±4.02) | (8.1±0.47) | (17.7±2.06) |
|             | 50                    | (58.2±2.17) | (7.8±1.42) | (16.7±3.22) |
|             | 80                    | (59.3±2.92) | (6.3±2.57) | (18.6±2.58) |

Data are presented as the mean±standard deviation. aP<0.05, vs. control group; bP<0.05 vs. control group and 20 µmol/l PDTC group; cP<0.05, vs. control group and 50 µmol/l PDTC group; dP<0.05, vs. TMZ group and 20 µmol/l PDTC group; eP<0.05, vs. control group, 50 µmol/l PDTC group and TMZ + 20 µmol/l PDTC group. All comparisons were carried out using one-way analysis of variance followed by least significant difference analysis or by the Kruskal-Wallis test. TMZ, temozolomide; PDTC, pyrrolidine dithiocarbamate.

Figure 4. PDTC treatment suppresses MGMT, BCL-XL and survivin expression levels. (A) RT-qPCR results demonstrated that mRNA levels of MGMT were markedly decreased in PDTC-treated cells. (B) The BCL-XL mRNA level was significantly lower following PDTC treatment. (C) The mRNA level of survivin was also much lower in the PDTC group. *P<0.05 compared with control cells. (D) Western blotting results demonstrated lower MGMT, BCL-XL and survivin protein expression levels in the PDTC treated cells, compared with the control U251 cells. PDTC, pyrrolidine dithiocarbamate; MGMT, O-6-methylguanine-DNA methyltransferase; BCL-XL, B-cell lymphoma extra-large; RT-qPCR, reverse transcription-quantitative polymerase chain reaction.
instance, in glioblastoma initial cells, resveratrol was identified to block MGMT upregulation induced by TMZ treatment via inhibiting NF-κB activation (15). Therefore, downregulation of the NF-κB/MGMT signaling pathway is a feasible strategy in order to overcome TMZ-resistance. For example, BAY 11-7082, a specific IκB kinase (IKK) inhibitor leading to the de-activation of the NF-κB signaling pathway, sensitized selected U251 TMZ-resistant cells (TR/U251) to TMZ treatment, resulting in substantial cell death (37). However, Bay 11-7082 may induce cell death independent from inhibiting the activation of the NF-κB signaling pathway (46), and this is the reason for the selection of PDTC, instead of Bay 11-7082 in the present study.

In addition to the regulation of MGMT expression, the impact of NF-κB activity on its canonical target genes, including BCL-XL, survivin, BCL-2, inhibitor of apoptosis 1/2 (IAP1/IAP2), TNF receptor associated factor 1/2, VEGF, matrix metalloproteinase 9 (MMP9) and cyclin D1, are also worth further study for glioma therapy. BCL-XL, BCL-2, survivin and IAP1/IAP2 are key anti-apoptotic factors contributing to cell survival, and are closely associated with the progression and chemotherapeutic or radiotherapy resistance of various types of cancer (47-49). BCL-XL upregulation by signal transducer and activator of transcription 3, contributes to mutant Kirsten rat sarcoma-mediated apoptosis resistance in colorectal cancer (49). In a recent study with 117 ovarian epithelial neoplasms, survivin overexpression was identified in the majority of malignant cases and was associated with patient prognosis, indicating a crucial role in the development of epithelial ovarian neoplasms (50). Furthermore, it has previously been revealed that survivin expression may be upregulated by treatment in certain lymphoid or myeloid tumors (48). As a consequence, a large number of novel antagonist and inhibitors of these anti-apoptotic factors have been developed, and a number of them demonstrated good clinical results (47,51). The overexpression of these anti-apoptotic factors may be induced by highly activated upstream NF-κB; therefore, inhibiting NF-κB activity may be a potential method by which to suppress tumors with overexpressed BCL-XL, BCL-2 or survivin (52).

In conjunction, the present study identified that the expression of BCL-XL and survivin are significantly inhibited by PDTC treatment in U251 cells (Fig. 4). Furthermore, NF-κB activity and, consequently, cyclin D1, COX-2, BCL-XL and BCL-2 expression levels may be suppressed in vivo in prostate tumors by Apigenin, which has been administrated to transgenic adenocarcinoma mouse prostates (53). Similarly, MGMT, BCL-XL, BCL-2 and survivin serve important roles in NF-κB mediated therapeutic resistance (54). Conversely, combining traditional agents with novel inhibitors of these survival and anti-apoptotic factors may be a promising cancer therapy strategy (55). Downregulated anti-apoptotic factors may be an additional mechanism underlying PDTC-enhanced TMZ efficacy in the present study, particularly considering that NF-κB and its downstream anti-apoptotic factors are often stimulated by radiotherapy and chemotherapy (54). The present study also demonstrated TMZ induced the upregulation of BCL-XL and survivin in U251 cells. Additionally, a lower level of BCL-XL, not survivin, was demonstrated in PDTC + TMZ treated cells, as compared with TMZ only treated cells (Fig. 5). Therefore, a reduction BCL-XL expression may serve a role in PDTC induced U251 cell sensitivity to TMZ, whereas the expression level of survivin may not be altered significantly in TMZ treated cells by PDTC, at a low concentration of ~50 µmol/l.

The results of the present study in regards to survivin were in accordance with the findings of Elhag et al (56), which revealed that the ability of silibinin, a natural plant component, to potentiate the cytotoxic efficacy of TMZ in human LN229, U87 and A172 glioblastoma cells was unrelated to survivin protein levels, whereas silibinin may attenuate metastatic processes by suppressing NF-κB and the downstream gene, MMP9. Additionally, it was revealed that expression levels of cyclin D1 were not significantly altered by PDTC treatment, although the addition of PDTC led to an enhanced G1/G0 phase arresting effect (56).

The present study demonstrated that PDTC, a widely tested inhibitor of NF-κB activation as well as an antioxidant

**Figure 5.** PDTC counteracts the upregulation of MGMT and BCL-XL induced by TMZ treatment. (A) RT-qPCR results revealed that mRNA level of MGMT in TMZ-treated cells was significantly higher than that in control cells and TMZ + PDTC-treated cells. *P<0.05 compared with control cells, †P<0.05 compared with TMZ-treated cells. (B) The mRNA level of BCL-XL in TMZ-treated cells was higher than that in control cells and TMZ + PDTC-treated cells. *P<0.05 compared with control cells, †P<0.05 compared with TMZ-treated cells. (C) The survivin mRNA level in TMZ-treated cells was much higher than that in control cells, but showed no statistical difference between TMZ-treated cells and TMZ + PDTC treated cells. *P<0.05 compared with control cells. (D) Western blotting results demonstrated that MGMT, BCL-XL and survivin protein levels in TMZ treated cells were higher compared with the control cells; MGMT and BCL-XL protein levels of TMZ + PDTC treated cells were low compared with TMZ treated cells; however, the survivin protein level between TMZ + PDTC treated and TMZ treated cells demonstrated no obvious difference. PDTC, pyrroldine dithiocarbamate; MGMT, O-6-methylguanine-DNA methyltransferase; BCL-XL, B-cell lymphoma extra-large; TMZ, temozolomide; RT-qPCR, reverse transcription-quantitative polymerase chain reaction.
and metal chelator, may inhibit cell proliferation, induce apoptosis and cell cycle arrest and enhance sensitivity to TMZ in U251 glioma cells. It was also revealed that PTDC sensitized U251 cells to TMZ, mainly via blocking the NF-κB and NF-κB/BCL-XL signaling pathways that were activated by TMZ treatment. Currently, a large number of anti-NF-κB drugs have been developed for cancer therapy (57); the results of the present study may provide specific aid in furthering the understanding of the chemotherapeutic effects, and the underlying mechanisms involved in inhibiting NF-κB in glioma cells, thus providing an important theoretical basis for developing NF-κB inhibitors with greater efficacy and improved methods of cancer treatment.

Acknowledgements

The present study was supported by The National Natural Science Foundation of China (grant no. NSFC: 81272783) and The National Key Technology Research and Development Program of the Ministry of Science and Technology of China (grant no. 2014BAI04B02). The authors thank Mrs Xiaohong Yang (The National Institute of Biological Sciences, Beijing, China) for her contributions and Dr Weiliang Jiang (Shanghai Jiaotong University School of Medicine, Shanghai, China) for his comments on the manuscript.

References

1. Ohgaki H and Kleihues P: Epidemiology and etiology of gliomas. Acta Neuropathol 109: 93-108, 2005.
2. Louis DN, Perry A, Burger P, Ellison DW, Reifenberger G, von Deimling A, Aldape K, Brat D, Collins VP, Eberhart C, et al: International society of neuropathology-haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol 24: 429-435, 2014.
3. Carlsson SK, Brothers SP and Wahlestedt C: Emerging treatment strategies for glioblastoma multiforme. EMBO Mol Med 6: 1359-1370, 2014.
4. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, et al: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase II study: 3-year analysis of the EORTC-NCIC trial. Lancet Oncol 10: 459-466, 2009.
5. Gilbert MR, Friedman HS, Kutscher JS, Prados MD, Olson JJ, Reaman GH and Zaknoen SL: A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy. Neuro Oncol 4: 261-267, 2002.
6. Jiao J, Fu W, Muller-Pillasch F, Zamboni M, Pfeffer LM: Constitutive activation of signal transducer and activator of transcription 3 (STAT3) and nuclear factor-xB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 12: 115-130, 2007.
7. Cheng ZX, Sun B, Wang SJ, Gao Y, Zhang YM, Zhou HX, Jia G, Wang YW, Kong R, Pan SH, et al: Nuclear factor-xB-dependent epithelial to mesenchymal transition induced by HIF-1α activation in pancreatic cancer cells under hypoxic conditions. PLoS One 6: e23752, 2011.
8. Garner JM, Fan M, Yang CH, Du Z, Simis M, Davidoff AM and Pfeffer LM: Constitutive activation of signal transducer and activator of transcription 3 (STAT3) and nuclear factor-xB signaling in glioblastoma cancer stem cells regulates the Notch pathway. J Biol Chem 288: 26167-26176, 2013.
9. Huber MA, Azoitie N, Baumann B, Grünert S, Sommer A, Peberdy KB, Kraut N, Beug H and Wirth T NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest 114: 569-581, 2004.
10. Cheng ZX, Wang DW, Liu T, Liu WX, Xia WB, Xu J, Zhang YH, Qu YK, Guo LQ, Ding L, et al: Effects of the HIF-1α and NF-xB loop on epithelial-mesenchymal transition and chemoresistance induced by hypoxia in pancreatic cancer cells. Oncol Rep 31: 1891-1898, 2014.
11. Puliappadamba VT, Hatanpaa KJ, Chakraborty S and Habib AA: The role of NF-kappaB in the pathogenesis of glioma. Cancer Cell Oncol 1: 6963478, 2014.
12. Caporali S, Levati L, Graziani G, Muzi A, Atzori MG, Bonmassar E, Palmieri G, Ascierto PA and D’Atri S: NF-xB is activated in response to temozolomide in an AKT-dependent manner and confers protection against the growth suppressive effect of the drug. J Transl Med 10: 252, 2012.
13. Lavon I, Fuchs D, Zrihan D, Efroni G, Zelikovitch B, Fellig Y and Siegal T: Novel mechanism whereby nuclear factor κB antagonism of nuclear factor κB in human glioma and mutant p53. Oncogene 18: 6938-6947, 1999.
14. Karin M, Cao Y, Getren FR and Li ZW: NF-kappaB in cancer: From innocent bystander to major culprit. Nat Rev Cancer 2: 301-310, 2002.
15. Taniwaki MI, Davis RE, Demchenko Y, Bellamy L, Gabrea A, Zhan F, Lenz G, Hanamura I, Wright G, Xiao W, et al: Frequent engagement of the classical and alternative NF-kappaB signaling pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 12: 115-130, 2007.
16. Garner JM, Fan M, Yang CH, Du Z, Simis M, Davidoff AM and Pfeffer LM: Constitutive activation of signal transducer and activator of transcription 3 (STAT3) and nuclear factor-xB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 12: 115-130, 2007.
17. Karin M, Cao Y, Green FR and Li ZW: NF-kappaB in cancer: From innocent bystander to major culprit. Nat Rev Cancer 2: 301-310, 2002.
18. Taniwaki MI, Davis RE, Demchenko Y, Bellamy L, Gabrea A, Zhan F, Lenz G, Hanamura I, Wright G, Xiao W, et al: Frequent engagement of the classical and alternative NF-kappaB signaling pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 12: 115-130, 2007.
19. Cunnick GW, Kraczyk D, Schuster H, Ho SC, Sproat KL, Garcia ME, de Alava AI and Rabinovitch PS: NF-kappaB and mutant p53. Oncogene 18: 6938-6947, 1999.
et al: The NF-κB transcription factors. PLoS One 8: e59292, 2013.

31. Wang L, Wei B, Hu G, Wang L, Bi M, Sun Z and Jin Y: Screening of differentially expressed genes associated with human glioblastoma and functional analysis using a DNA microarray. Mol Med Rep 12: 1991-1996, 2015.

32. Wang H, Wang H, Zhang W, Huang HJ, Liao WS and Fuller GN: Analysis of the activation status of Akt, NFkappaB, and Stat3 in human diffuse gliomas. Lab Invest 84: 941-951, 2004.

33. Sun P, Mu Y and Zhang S: A novel NF-κB/MMP-3 signal pathway involves in the aggressiveness of glioma promoted by Bmi-1. Tumour Biol 35: 12721-12727, 2014.

34. Wang Z, Banerjee S, Li Y, Rahman KM, Zhang Y and Sarkar FH: Down-regulation of notch-1 inhibits invasion by inactivation of nuclear factor-kappaB, vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells. Cancer Res 66: 2778-2784, 2006.

35. Wang CY, Cusack JC Jr, Liu R and Baldwin AS Jr: Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med 5: 412-417, 1999.

36. Kim HJ, Hawke N and Baldwin AS: NF-kappab and IKK as therapeutic targets in cancer. Cell Death Differ 13: 738-747, 2006.

37. Wang X, Jia L, Jin X, Liu Q, Cao W, Gao X, Yang M and Sun B: NF-κB inhibitor reverses temozolomide resistance in human glioma TR/U251 cells. Oncol Lett 9: 2586-2590, 2015.

38. Zhang L, Ren X, Cheng Y, Liu X, Allen JE, Zhang Y, Yuan Y, Huang SY, Yang W, Berg A, et al: The NFκB inhibitor, SNS50, induces differentiation of glioma stem cells and suppresses their oncogenic phenotype. Cancer Biol Ther 15: 602-614, 2015.

39. Qin JD, Cao ZH, Li XF, Kang XL, Xue Y, Li YL, Zhang D, Liu XY and Xue YZ: Effect of ammonium pyrrolidine dithiocarbamate inhibits nuclear factor -κB, vascular endothelial growth factor, and apoptosis in rats with severe acute pancreatitis. Mol Hum Reprod 17: 175-181, 2011.

40. Lan F, Yang Y, Han J, Wu Q, Yu H and Yue X: Sulforaphane reverses chemo-resistance to temozolomide in glioblastoma cells by NF-κB-dependent pathway downregulating MGMT expression. Int J Oncol 48: 559-568, 2016.

41. Song T, Li H, Tian Z, Xu C, Liu J and Guo Y: Disruption of NF-κB signaling by fluoxetine attenuates MGMT expression in glioma cells. Oncotarget 8: 21557-21571, 2015.

42. Shukla S, Shankar E, Fu P, MacLennan GT and Gupta S: Suppression of NF-κB and NF-κB-regulated gene expression by apigenin through IκBα and IKK pathway in TRAMP mice. PLoS One 10: e0138710, 2015.

43. Barbieri G, Ripamonti M, Casarino C, Augello G, Costantini F, Bravatà V, Minafra L, Russo G, Forte GI, Cammarata FP, Seremak-Mrozikiewicz A and Plewka A: Survivin in ovary tumors. Ginekol Pol 86: 525-530, 2015.

44. Zhou W, Xu J, Gelston E, Wu X, Zou Z, Wang B, Zeng Y, Wang H, Liu A, Xu L and Liu Q: Inhibition of Bel-κB inhibits polyplody resistance and leads to apoptotic cell death in acute myeloid leukemia cells. Oncotarget 6: 21557-21571, 2015.

45. Vallianou NG, Evangelopoulos A, Schizas N and Kazakis C: Potential anticancer properties and mechanisms of action of curcumin. Anticancer Res 35: 645-651, 2015.

46. Opferman JT: Attacking cancer's Achilles heel: Antagonism of anti-apoptotic BCL-2 family members. FEBS J 283: 2661-2675, 2016.

47. Hall RL, Beck FW, Al-Katib AM and Mohammad RM: Treatment-induced expression of anti-apoptotic proteins in WSU-CLL, a human chronic lymphocytic leukemia cell line. J Drug Target 9: 329-339, 2001.

48. Walli N, Beck FW, Al-Katib AM and Mohammad RM: Treatment-induced expression of anti-apoptotic proteins in WSU-CLL, a human chronic lymphocytic leukemia cell line. J Drug Target 9: 329-339, 2001.